Adverse effects


Select item(s)
Key Findings
Among all treatment group patients, Lopinavir/ritonavir group patients experienced more serious adverse effects (52.8% in the lopinavir/ritonavir group vs. 38.5% in the control group; 54.2% in the lopinavir/ritonavir plus IFN-Ŗ-1a group vs. 38.5% in the control group). 44.1% of patients in the Hydroxychloroquine treated group had Serious adverse effects.
PMID
Title Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial
Author(s) name-
Journal
Impact factor
Citation count
Date of publishing-
The case study is of a 66-year-old man who experienced acute colic perforation after being treated with tocilizumab and corticosteroids for his COVID-19 diagnosis.
PMID 32402416
Title Intestinal perforation in patient with COVID-19 infection treated with tocilizumab and corticosteroids. Report of a clinical case
Author(s) nameGonz√°lvez Guardiola P, D√≠ez Ares J√Ā, Peris Tom√°s N, Sebasti√°n Tom√°s JC, Navarro Mart√≠nez S.
Journal Cir Esp
Impact factor0.36
Citation count1
Date of publishing2021 Feb
Compared to the placebo group patients, the fluvoxamine-treated group patients showed less serious adverse effects.
PMID 33180097
Title Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19
Author(s) nameLenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM.
Journal JAMA
Impact factor14.78
Citation count6
Date of publishing2020 Dec 8
Several common serious adverse effects were observed between two groups of patients (IFX-1 and control). In the IFX-1 group, 23 serious adverse effects occurred in 9 out of 15 patients. In the control group, 19 adverse effects occurred in 7 out of 15 patients.
PMID 33015643
Title Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
Author(s) nameVlaar APJ, de Bruin S, Busch M, Timmermans SAMEG, van Zeggeren IE, Koning R, Ter Horst L, Bulle EB, van Baarle FEHP, van de Poll MCG, Kemper EM, van der Horst ICC, Schultz MJ, Horn J, Paulus F, Bos LD, Wiersinga WJ, Witzenrath M, Rueckinger S, Pilz K, Brouwer MC, Guo RF, Heunks L, van Paassen P, Riedemann NC, van de Beek D.
Journal Lancet Rheumatol
Impact factor<3years
Citation count8
Date of publishing2020 Dec
A significant increase in Aminotransferase levels was observed in patients treated with Tocilizumab (TCZ), compared to Anakinra (ANA) treated group patients.
PMID 32843231
Title High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients
Author(s) nameIglesias-Juli√°n E, L√≥pez-Veloso M, de-la-Torre-Ferrera N, Barraza-Vengoechea JC, Delgado-L√≥pez PD, Colazo-Burlato M, Ubeira-Iglesias M, Montero-Balad√≠a M, Lorenzo-Mart√≠n A, Minguito-de-la-Iglesia J, Garc√≠a-Mu√Īoz JP, Sanllorente-Sebasti√°n R, Vicente-Gonz√°lez B, Alem√°n-Alem√°n A, Buz√≥n-Mart√≠n L.
Journal J Autoimmun
Impact factor7.32
Citation count3
Date of publishing2020 Dec
Adverse effects were similar between two groups (Remdesivir and placebo) of patients. Serious adverse effects were reported in 131 patients in the Remdesivir group and 163 patients in the placebo group.
PMID 32445440
Title Remdesivir for the Treatment of Covid-19 Final Report
Author(s) nameBeigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members.
Journal N Engl J Med
Impact factor37.91
Citation count690
Date of publishing2020 Nov 5
The patient treated with Remedesivir experienced acute liver failure which improved with the treatment of acetylcysteine
PMID 33006138
Title Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series
Author(s) nameCarothers C, Birrer K, Vo M.
Journal Pharmacotherapy
Impact factor3.17
Citation count1
Date of publishing2020 Nov
The patient treated with Remedesivir experienced acute liver failure which improved with the treatment of acetylcysteine
PMID 33006138
Title Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series
Author(s) nameCarothers C, Birrer K, Vo M.
Journal Pharmacotherapy
Impact factor3.17
Citation count1
Date of publishing2020 Nov
Adverse effects were common between treatment groups (hydroxychloroquine and control group). The most common adverse effects were gastrointestinal discomfort, diarrhea, headache, nausea, or dizziness. Few serious adverse events were also reported.
PMID 33082342
Title A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics
Author(s) nameLyngbakken MN, Berdal JE, Eskesen A, Kvale D, Olsen IC, Rueegg CS, Rangberg A, Jonassen CM, Omland T, R√łsj√ł H, Dalgard O.
Journal Nat Commun
Impact factor11.8
Citation count4
Date of publishing2020 Oct 20
Patients with adverse effects were more in the HCQ group than the placebo group. The most common adverse effects were stomach upset, nausea, abdominal pain, diarrhea, or vomiting.
PMID 32673060
Title Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 A Randomized Trial
Author(s) nameSkipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, Williams DA, Okafor EC, Pullen MF, Nicol MR, Nascene AA, Hullsiek KH, Cheng MP, Luke D, Lother SA, MacKenzie LJ, Drobot G, Kelly LE, Schwartz IS, Zarychanski R, McDonald EG, Lee TC, Rajasingham R, Boulware DR.
Journal Ann Intern Med
Impact factor11.75
Citation count83
Date of publishing2020 Oct 20
Out of 25 patients treated with Tocilizumab, 23 experienced at least one adverse event. Anemia, alanine aminotransferase (ALT) rise, and QT interval prolongation were the most frequent adverse events.
PMID 32369191
Title Tocilizumab for the treatment of severe coronavirus disease 2019
Author(s) nameAlattar R, Ibrahim TBH, Shaar SH, Abdalla S, Shukri K, Daghfal JN, Khatib MY, Aboukamar M, Abukhattab M, Alsoub HA, Almaslamani MA, Omrani AS.
Journal J Med Virol
Impact factor2.07
Citation count58
Date of publishing2020 Oct
This observational study is based on an algorithm that was structured to use tocilizumab for the treatment of COVID-19 patients with Cytokine Release Syndrome. Following tocilizumab treatment, oxygenation and inflammatory biomarkers improved. And D-dimer and soluble IL-2 receptor levels increased significantly.
PMID 32553536
Title Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes
Author(s) namePrice CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M.
Journal Chest
Impact factor7.22
Citation count41
Date of publishing2020 Oct
3 out of 4 patients, was observed to have serious adverse events.
PMID 32418190
Title Early experience with remdesivir in SARS-CoV-2 pneumonia
Author(s) nameDurante-Mangoni E, Andini R, Bertolino L, Mele F, Florio LL, Murino P, Corcione A, Zampino R.
Journal Infection
Impact factor2.84
Citation count5
Date of publishing2020 Oct
4 Out of 5 patients treated with Remdesivir showed side effects.
PMID 32619764
Title Case report study of the first five COVID-19 patients treated with remdesivir in France
Author(s) nameDubert M, Visseaux B, Isernia V, Bouadma L, Deconinck L, Patrier J, Wicky PH, Le Pluart D, Kramer L, Rioux C, Le Hingrat Q, Houhou-Fidouh N, Yazdanpanah Y, Ghosn J, Lescure FX.
Journal Int J Infect Dis
Impact factor3.42
Citation count6
Date of publishing2020 Sep
Side effects were more common in patients treated with hydroxychloroquine than with placebo. The most common side effects were nausea, loose stools, and abdominal discomfort.
PMID 32492293
Title A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
Author(s) nameBoulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, Skipper CP, Nascene AA, Nicol MR, Abassi M, Engen NW, Cheng MP, LaBar D, Lother SA, MacKenzie LJ, Drobot G, Marten N, Zarychanski R, Kelly LE, Schwartz IS, McDonald EG, Rajasingham R, Lee TC, Hullsiek KH.
Journal N Engl J Med
Impact factor37.91
Citation count268
Date of publishing2020 Aug 6
Of 52 convalescent plasma-treated patients, 2 experienced adverse effects within an hour of transfusion. The observed adverse effects were Chills, rashes, shortness of breath, cyanosis, and severe dyspnea.
PMID 32492084
Title Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19
Author(s) nameLi L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, Kong Y, Ren L, Wei Q, Mei H, Hu C, Tao C, Yang R, Wang J, Yu Y, Guo Y, Wu X, Xu Z, Zeng L, Xiong N, Chen L, Wang J, Man N, Liu Y, Xu H, Deng E, Zhang X, Li C, Wang C, Su S, Zhang L, Wang J, Wu Y, Liu Z.
Journal JAMA
Impact factor14.78
Citation count197
Date of publishing2020 Aug 4
In this multi-center observational study, severe COVID-19 patients were treated with hyperimmune plasma therapy to reduce mortality. After transfusions, five serious adverse events occurred in four patients.
PMID 33256382
Title Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial
Author(s) namePerotti C, Baldanti F, Bruno R, Del Fante C, Seminari E, Casari S, Percivalle E, Glingani C, Musella V, Belliato M, Garuti M, Meloni F, Frigato M, Di Sabatino A, Klersy C, De Donno G, Franchini M, Covid-Plasma Task Force.
Journal Haematologica
Impact factor7.53
Citation count26
Date of publishing2020 Jul 23
The group of patients treated with only HCQ or HCQ + Azithromycin showed more serious adverse events (like Cardiac arrest, arrhythmia, and QT prolongation) compared to patients who did not receive any drug.
PMID 32392282
Title Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Author(s) nameRosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, Weinberg P, Kirkwood J, Muse A, DeHovitz J, Blog DS, Hutton B, Holtgrave DR, Zucker HA.
Journal JAMA
Impact factor14.78
Citation count313
Date of publishing2020 Jun 23
This study compares the effect of convalescent plasma therapy against the control group on viral shedding and survival in COVID-19 patients with serious respiratory failure.
PMID 32348485
Title Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019
Author(s) nameZeng QL, Yu ZJ, Gou JJ, Li GM, Ma SH, Zhang GF, Xu JH, Lin WB, Cui GL, Zhang MM, Li C, Wang ZS, Zhang ZH, Liu ZS.
Journal J Infect Dis
Impact factor4.73
Citation count78
Date of publishing2020 Jun 16
60% of patients had side effects with Remdesivir treatment. Serious side events were also observed in 23% of patients. The most common adverse effects were diarrhea, rash, renal impairment, increased hepatic enzymes, and hypotension.
PMID 32275812
Title Compassionate Use of Remdesivir for Patients with Severe Covid-19
Author(s) nameGrein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D'Arminio Monforte A, Ismail S, Kato H, Lapadula G, L'Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T.
Journal N Engl J Med
Impact factor37.91
Citation count776
Date of publishing2020 Jun 11
A rapid increase in transaminases (aspartate aminotransferase and alanine aminotransferase) was observed after the introduction of HCQ. And a reduction in transaminases was observed after the drug was discontinued.
PMID 32314698
Title Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with COVID-19
Author(s) nameFalcão MB, Pamplona de Góes Cavalcanti L, Filgueiras Filho NM, Antunes de Brito CA.
Journal Am J Trop Med Hyg
Impact factor2.25
Citation count5
Date of publishing2020 Jun
2.4% of patients reported mild adverse effects when treated with HCQ and azithromycin.
PMID 32387409
Title Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
Author(s) nameMillion M, Lagier JC, Gautret P, Colson P, Fournier PE, Amrane S, Hocquart M, Mailhe M, Esteves-Vieira V, Doudier B, Aubry C, Correard F, Giraud-Gatineau A, Roussel Y, Berenger C, Cassir N, Seng P, Zandotti C, Dhiver C, Ravaux I, Tomei C, Eldin C, Tissot-Dupont H, Honoré S, Stein A, Jacquier A, Deharo JC, Chabrière E, Levasseur A, Fenollar F, Rolain JM, Obadia Y, Brouqui P, Drancourt M, La Scola B, Parola P, Raoult D.
Journal Travel Med Infect Dis
Impact factor3.42
Citation count132
Date of publishing2020 May-Jun
Adverse effects in the lopinavir-ritonavir group were observed, 19 serious effects out of which 4 were serious gastrointestinal effects.
PMID 32187464
Title A Trial of LopinavirRitonavir in Adults Hospitalized with Severe Covid-19
Author(s) nameCao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C.
Journal N Engl J Med
Impact factor37.91
Citation count1546
Date of publishing2020 May 7
Common adverse effects were observed in 48% of patients in the combination group (beta-1b, lopinavir-ritonavir, and ribavirin) and 49% of patients in the control group (lopinavir-ritonavir). One serious adverse effect was observed in the control group.
PMID 32401715
Title Triple combination of interferon beta-1b, lopinavirritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
Author(s) nameHung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, Ng YY, Lo J, Chan J, Tam AR, Shum HP, Chan V, Wu AK, Sin KM, Leung WS, Law WL, Lung DC, Sin S, Yeung P, Yip CC, Zhang RR, Fung AY, Yan EY, Leung KH, Ip JD, Chu AW, Chan WM, Ng AC, Lee R, Fung K, Yeung A, Wu TC, Chan JW, Yan WW, Chan WM, Chan JF, Lie AK, Tsang OT, Cheng VC, Que TL, Lau CS, Chan KH, To KK, Yuen KY.
Journal Lancet
Impact factor43.38
Citation count352
Date of publishing2020 May 30
Out of 155 patients in the Remdesivir group, 102 patients had adverse effects. Of 78 patients in the placebo group, 50 patients had adverse effects. 28 and 20 serious adverse effects were reported in the Remdesivir group and placebo group, respectively.
PMID 32423584
Title Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Author(s) nameWang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C.
Journal Lancet
Impact factor43.38
Citation count738
Date of publishing2020 May 16